Malyarov 1999.
| Methods | Allocation: randomised (no further description). Blindness: independent observers blind to treatment. Duration: 6 months. Consent: not stated. Setting: not stated. | |
| Participants | Diagnosis: schizophrenia (ICD‐10). N=43. Age: mean ˜ 25 years. Sex: 28M, 15F. History: acute or post‐acute phase, hospitalised, duration of illness < 3 years. Exclusions: not stated. | |
| Interventions | 1. Risperidone: 3‐6mg/day. N=10. 2. Haloperidol: 5‐20mg/day. N=18. 3. Olanzapine: 5‐15mg/day. N=15. | |
| Outcomes | Leaving the study early. Unable to use ‐ Global effect: (no data). Mental State: PANSS (no SD). |
|
| Notes | Conference abstract only. Only risperidone and haloperidol data used in this review. | |
| Risk of bias | ||
| Bias | Authors' judgement | Support for judgement |
| Allocation concealment? | Unclear risk | B ‐ Unclear |